View ValuationNIOX Group 将来の成長Future 基準チェック /26NIOX Group利益と収益がそれぞれ年間17.4%と6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に12.5% 11.9%なると予測されています。主要情報17.4%収益成長率11.87%EPS成長率Medical Equipment 収益成長13.4%収益成長率6.0%将来の株主資本利益率12.50%アナリストカバレッジLow最終更新日21 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesDeclared Dividend • May 20Dividend of UK£0.015 announcedShareholders will receive a dividend of UK£0.015. Ex-date: 21st May 2026 Payment date: 22nd June 2026 Dividend yield will be 2.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio). However, it is well covered by cash flows (46% cash payout ratio). The dividend has increased by an average of 24% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 1.9% to bring the payout ratio under control. EPS is expected to grow by 40% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.お知らせ • Apr 22NIOX Group Plc, Annual General Meeting, May 21, 2026NIOX Group Plc, Annual General Meeting, May 21, 2026. Location: the companys registered office magdalen centre, 1 robert robinson ave, the oxford science park, england, ox4 4ga, oxford United Kingdomお知らせ • Mar 25Niox Group plc Recommends Final Dividend for the Year Ended 31 December 2025NIOX Group Plc announced that the Board recommended the payment of a final dividend of 1.55 pence per fully paid ordinary share (2024: 1.25 pence). The aggregate amount of the proposed dividend expected to be paid after the reporting date, out of retained earnings at 31 December 2025, but not recognized as a liability at year end is £6.5 million (2024: £5.0 million).お知らせ • Mar 20NIOX Group Plc to Report Fiscal Year 2025 Results on Mar 24, 2026NIOX Group Plc announced that they will report fiscal year 2025 results on Mar 24, 2026お知らせ • Jul 08NIOX Group Plc to Report First Half, 2025 Results on Sep 30, 2025NIOX Group Plc announced that they will report first half, 2025 results on Sep 30, 2025お知らせ • Apr 03Niox Group plc Recommends Final Dividend for the Year Ended December 31, 2024NIOX Group Plc recommended final dividend of 1.25 pence per share in respect of the year ended December 31 2024.お知らせ • Mar 21An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million.An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million on February 20, 2025. As on March 6, 2025, The Board of NIOX Group received a revised proposal from Keensight Capital on behalf of funds managed or advised by it ("Keensight") regarding a possible cash offer to acquire the entire issued and to be issued ordinary share capital of NIOX (the "Proposal") at an offer price of £0.81 per NIOX share, the Proposal follows a previous unsolicited approach by Keensight to acquire NIOX on February 20, 2025 at an offer price of £0.78 per NIOX share. The Proposal is subject to the satisfaction or waiver by Keensight of a number of pre-conditions, including the completion of satisfactory due diligence. Accordingly, the Board has agreed to provide Keensight with access to due diligence. Discussions with Keensight remain at a preliminary stage and, as such, there can be no certainty that any firm offer will be made for the Company by Keensight, nor as to the terms of any such offer, should one be made. Lazard & Co., Limited and Singer Capital Markets Advisory LLP acted as financial advisor to NIOX.お知らせ • Jan 17NIOX Group Plc, Annual General Meeting, May 14, 2025NIOX Group Plc, Annual General Meeting, May 14, 2025.お知らせ • Jan 16+ 1 more updateNIOX Group Plc Appoints Jonathan Emms as Chief Executive OfficerNIOX Group Plc announced Jonathan Emms, currently Chief Operating Officer, has been appointed Chief Executive Officer with immediate effect.お知らせ • Dec 04NIOX Group Plc to Report Fiscal Year 2024 Results on Apr 01, 2025NIOX Group Plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 01, 2025Reported Earnings • Sep 26First half 2024 earnings released: EPS: UK£0.01 (vs UK£0.007 in 1H 2023)First half 2024 results: EPS: UK£0.01 (up from UK£0.007 in 1H 2023). Revenue: UK£21.0m (up 12% from 1H 2023). Net income: UK£4.40m (up 52% from 1H 2023). Profit margin: 21% (up from 15% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 24NIOX Group Plc (AIM:NIOX) announces an Equity Buyback for 26,250,000 shares, representing 6.19% for £21 million.NIOX Group Plc (AIM:NIOX) announces a share repurchase program. Under the program, the company will repurchase up to 26,250,000 shares, representing 6.19% of its share capital for £21 million. The shares will be repurchased at £0.8 per share. The company intends to hold 10,000,000 shares in treasury and the remaining shares will be cancelled. The record date for the offer is October 15, 2024. The offer will be valid till October 15, 2024. The tender offer is subject to approval from shareholders in the Extraordinary General Meeting to be held on October 16, 2024. As of September 23, 2024, the company has 424,045,460 shares in issue.お知らせ • Aug 19NIOX Group Plc to Report First Half, 2024 Results on Sep 24, 2024NIOX Group Plc announced that they will report first half, 2024 results on Sep 24, 2024お知らせ • Jul 01Niox Group plc Appoints Robert Naylor as Non-Executive Director and Chair of the Audit and Risk CommitteeNIOX Group plc announced the appointment of Robert Naylor, aged 49, as Non-Executive Director and Chair of the Audit and Risk Committee, with immediate effect. Robert has over 25 years' experience in capital markets specialising in healthcare and investment companies and is currently Chief Executive Officer of Intuitive Investments Group plc, an investment company which is quoted on the Specialist Fund Segment of the London Stock Exchange's Main Market, providing investors with exposure to a portfolio of fast-growing technology and life sciences businesses. Additionally, Robert is Non-Executive Chairman of Hipgnosis Songs Fund Limited, a FTSE 250 company, which is currently subject to a recommended cash offer by Lyra Bidco Limited, a newly-formed company indirectly wholly-owned by investment funds advised by affiliates of Blackstone Inc. Previously, Robert was Non-Executive Chairman of Round Hill Music Royalty Fund Limited and oversaw its sale to a company directly owned by Alchemy Copyrights, LLC, trading as Concord. He has also served as a Non-Executive Director of Light Science Technologies Holdings plc, an AIM-quoted controlled environment agriculture company. Earlier in his career Robert held various positions within JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited and Cenkos Securities plc. Robert is a qualified chartered accountant, having started his career with Ernst & Young in 1996. Current directorships/partnerships: Intuitive Investments Group Plc, IIG Assets Ltd, Hipgnosis SFH XX Limited, Hipgnosis SFH XIII Limited, Hipgnosis SFH XIX Limited, Hipgnosis SFH I Limited, Hipgnosis Holdings UK Limited, Rubyruby (London) Limited, Pb Songs Ltd, Kennedy Publishing & Productions Limited, Deamon Limited. Past directorships/partnerships: Round Hill Music Royalty Fund Limited, RHMRF2 Limited, RHMRF3 Limited, Light Science Technologies Holdings plc, Concord Copyrights No.1 Limited (formerly RHMRF1 Limited).Upcoming Dividend • May 16Upcoming dividend of UK£0.01 per shareEligible shareholders must have bought the stock before 23 May 2024. Payment date: 24 June 2024. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.7%).お知らせ • Apr 05NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024NIOX Group Plc announced on 26 March 2024 a proposed final dividend of 1.0 pence per ordinary share in respect of the financial year ended 31 December 2023. The proposed dividend is subject to shareholder approval at the Company's Annual General Meeting ("AGM") to be held on 22 May 2024. Following approval, the dividend will be paid on 24 June 2024 to shareholders on the register at the close of business on the record date of 24 May 2024, with an ex-dividend date of 23 May 2024.Recent Insider Transactions • Mar 31COO & Executive Director recently sold €171k worth of stockOn the 28th of March, Jonathan Emms sold around 234k shares on-market at roughly €0.73 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months.Reported Earnings • Mar 26Full year 2023 earnings releasedFull year 2023 results: Revenue: UK£36.8m (up 18% from FY 2022). Net income: UK£9.50m (down 33% from FY 2022). Profit margin: 26% (down from 45% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.お知らせ • Dec 27+ 1 more updateNIOX Group Plc, Annual General Meeting, May 22, 2024NIOX Group Plc, Annual General Meeting, May 22, 2024.Reported Earnings • Sep 28First half 2023 earnings released: EPS: UK£0.007 (vs UK£0.021 in 1H 2022)First half 2023 results: EPS: UK£0.007 (down from UK£0.021 in 1H 2022). Revenue: UK£18.8m (up 21% from 1H 2022). Net income: UK£2.90m (down 67% from 1H 2022). Profit margin: 15% (down from 57% in 1H 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth.New Risk • Sep 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 23% Last year net profit margin: 46% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (23% net profit margin).お知らせ • Jul 21NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023NIOX Group Plc announced a special dividend of 2.5 pence per share (equating to a return of cash of approximately £10.5 million) will be paid on 15 September 2023 to shareholders on the register as at the close of business on Friday 18 August 2023. The Group is now generating sufficient operating cashflow to permit both continued investment in the development of its business and the payment of ongoing dividends to shareholders.お知らせ • Jun 07NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023NIOX Group Plc announced that a special dividend of 2.5 pence per ordinary share will be paid on 15 September 2023 to shareholders on the register as at 18 August 2023. The associated ex-dividend date will be 17 August 2023.Board Change • Apr 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Mar 30COO & Executive Director recently sold €114k worth of stockOn the 28th of March, Jonathan Emms sold around 227k shares on-market at roughly €0.50 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months.Reported Earnings • Mar 22Full year 2022 earnings released: EPS: UK£0.034 (vs UK£0.006 in FY 2021)Full year 2022 results: EPS: UK£0.034 (up from UK£0.006 in FY 2021). Revenue: UK£31.3m (up 12% from FY 2021). Net income: UK£14.1m (up UK£11.8m from FY 2021). Profit margin: 45% (up from 8.2% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 17NIOX Group Plc to Report Fiscal Year 2022 Results on Mar 21, 2023NIOX Group Plc announced that they will report fiscal year 2022 results on Mar 21, 2023Board Change • Oct 31High number of new directorsNon-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020.Reported Earnings • Sep 16First half 2022 earnings released: EPS: UK£0 (vs UK£0.005 loss in 1H 2021)First half 2022 results: EPS: UK£0 (improved from UK£0.005 loss in 1H 2021). Revenue: UK£15.5m (up 6.2% from 1H 2021). Net income: UK£8.90m (up UK£10.9m from 1H 2021). Profit margin: 57% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.お知らせ • Jul 14Circassia Group Plc to Report First Half, 2022 Results on Sep 14, 2022Circassia Group Plc announced that they will report first half, 2022 results on Sep 14, 2022Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 14Circassia Group Plc, Annual General Meeting, May 13, 2022Circassia Group Plc, Annual General Meeting, May 13, 2022, at 09:00 Coordinated Universal Time. Location: Northbrook House, Robert Robinson Avenue, Oxford Science park Oxford United KingdomRecent Insider Transactions • Apr 02Executive Chairman recently bought €64k worth of stockOn the 29th of March, Ian Johnson bought around 150k shares on-market at roughly €0.43 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €197k worth in shares.Reported Earnings • Sep 18First half 2021 earnings released: UK£0.005 loss per share (vs UK£0.027 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£14.6m (up 28% from 1H 2020). Net loss: UK£2.00m (loss narrowed 79% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 18Executive Chairman recently bought €65k worth of stockOn the 16th of September, Ian Johnson bought around 150k shares on-market at roughly €0.43 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €133k worth in shares.お知らせ • May 27Beyond Air, Inc. Enters into Settlement Agreement with Circassia Group plcOn May 26, 2021, Beyond Air, Inc. entered into a settlement agreement with Circassia Group plc. Under the terms of the Settlement Agreement, the Company retains United States and China commercialization rights to LungFit® PH in exchange for returning $10.5 million in upfront and milestone payments received by the Company in 2019, over a two-year period commencing after the LungFit® PH receives United States Food and Drug Administration approval. Beginning in year three post-approval, Circassia will receive a quarterly royalty payment equal to 5% of LungFit® net sales in the United States, which will terminate once the aggregate payment reaches $6.0 million. The Company now holds full global rights to LungFit® PH.Recent Insider Transactions • Apr 08Executive Chairman recently bought €67k worth of stockOn the 6th of April, Ian Johnson bought around 200k shares on-market at roughly €0.34 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €120k worth in shares.Reported Earnings • Mar 25Full year 2020 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: UK£23.9m (down 62% from FY 2019). Net loss: UK£26.8m (loss narrowed 45% from FY 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.お知らせ • Jan 28Circassia Group Plc(AIM:CIR) dropped from FTSE All-Share Index (GBP)Circassia Group Plc(AIM:CIR) dropped from FTSE All-Share Index (GBP)お知らせ • Nov 13Circassia Group Plc Appoints Nicholas Mills as Non-Executive DirectorCircassia Group Plc announced the appointment of Nicholas Mills as Non-Executive Director, effective 13 November 2020. Nicholas is employed by Harwood Capital LLP. Nicholas joined Harwood Capital LLP in 2019 after spending five years at Gabelli Asset Management in New York. He acted primarily as a Research Analyst covering the multi-industrial space and also gained experience in Merger Arbitrage strategies and marketing Closed End Funds.お知らせ • Sep 02An unknown buyer acquired 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited for £3.9 million.An unknown buyer acquired 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited for £3.9 million on September 1, 2020. An unknown buyer completed the acquisition of 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited on September 1, 2020.業績と収益の成長予測DB:82C - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202858102021412/31/202754141919512/31/202650121517512/31/20254971415N/A6/30/20254651718N/A3/31/20254441618N/A12/31/20244231617N/A6/30/202439111213N/A3/31/202438101212N/A12/31/202337101112N/A9/30/20233691111N/A6/30/20233581111N/A3/31/2023331199N/A12/31/2022311477N/A9/30/2022301455N/A6/30/2022291333N/A3/31/202228822N/A12/31/202128211N/A9/30/202128-9-2-2N/A6/30/202127-19-5-5N/A3/31/202126-23-15-14N/A12/31/202024-27-24-24N/A9/30/202026-23-26-25N/A6/30/202027-18-28-26N/A3/31/202031-18-32-26N/A12/31/201935-17-35-25N/A9/30/201937-24N/A-38N/A6/30/201939-32N/A-51N/A3/31/201943-39N/A-46N/A12/31/201848-47N/A-41N/A9/30/201852-50N/A-36N/A6/30/201856-53N/A-31N/A3/31/201851-57N/A-44N/A12/31/201746-60N/A-58N/A6/30/201730-53N/A-54N/A3/31/201727-45N/A-55N/A12/31/201623-37N/A-57N/A9/30/201622-46N/A-63N/A6/30/201621-42N/A-69N/A3/31/201616-46N/A-62N/A12/31/201511-50N/A-56N/A9/30/20156-45N/A-48N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 82Cの予測収益成長率 (年間17.4% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: 82Cの収益 ( 17.4% ) はGerman市場 ( 16.9% ) よりも速いペースで成長すると予測されています。高成長収益: 82Cの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 82Cの収益 ( 6% ) German市場 ( 6.6% ) よりも低い成長が予測されています。高い収益成長: 82Cの収益 ( 6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 82Cの 自己資本利益率 は、3年後には低くなると予測されています ( 12.5 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/15 20:59終値2026/07/15 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NIOX Group Plc 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Julie SimmondsCanaccord GenuityKane SlutzkinDeutsche BankJens LindqvistInvestec Bank plc (UK)6 その他のアナリストを表示
Declared Dividend • May 20Dividend of UK£0.015 announcedShareholders will receive a dividend of UK£0.015. Ex-date: 21st May 2026 Payment date: 22nd June 2026 Dividend yield will be 2.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio). However, it is well covered by cash flows (46% cash payout ratio). The dividend has increased by an average of 24% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 1.9% to bring the payout ratio under control. EPS is expected to grow by 40% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.
お知らせ • Apr 22NIOX Group Plc, Annual General Meeting, May 21, 2026NIOX Group Plc, Annual General Meeting, May 21, 2026. Location: the companys registered office magdalen centre, 1 robert robinson ave, the oxford science park, england, ox4 4ga, oxford United Kingdom
お知らせ • Mar 25Niox Group plc Recommends Final Dividend for the Year Ended 31 December 2025NIOX Group Plc announced that the Board recommended the payment of a final dividend of 1.55 pence per fully paid ordinary share (2024: 1.25 pence). The aggregate amount of the proposed dividend expected to be paid after the reporting date, out of retained earnings at 31 December 2025, but not recognized as a liability at year end is £6.5 million (2024: £5.0 million).
お知らせ • Mar 20NIOX Group Plc to Report Fiscal Year 2025 Results on Mar 24, 2026NIOX Group Plc announced that they will report fiscal year 2025 results on Mar 24, 2026
お知らせ • Jul 08NIOX Group Plc to Report First Half, 2025 Results on Sep 30, 2025NIOX Group Plc announced that they will report first half, 2025 results on Sep 30, 2025
お知らせ • Apr 03Niox Group plc Recommends Final Dividend for the Year Ended December 31, 2024NIOX Group Plc recommended final dividend of 1.25 pence per share in respect of the year ended December 31 2024.
お知らせ • Mar 21An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million.An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million on February 20, 2025. As on March 6, 2025, The Board of NIOX Group received a revised proposal from Keensight Capital on behalf of funds managed or advised by it ("Keensight") regarding a possible cash offer to acquire the entire issued and to be issued ordinary share capital of NIOX (the "Proposal") at an offer price of £0.81 per NIOX share, the Proposal follows a previous unsolicited approach by Keensight to acquire NIOX on February 20, 2025 at an offer price of £0.78 per NIOX share. The Proposal is subject to the satisfaction or waiver by Keensight of a number of pre-conditions, including the completion of satisfactory due diligence. Accordingly, the Board has agreed to provide Keensight with access to due diligence. Discussions with Keensight remain at a preliminary stage and, as such, there can be no certainty that any firm offer will be made for the Company by Keensight, nor as to the terms of any such offer, should one be made. Lazard & Co., Limited and Singer Capital Markets Advisory LLP acted as financial advisor to NIOX.
お知らせ • Jan 17NIOX Group Plc, Annual General Meeting, May 14, 2025NIOX Group Plc, Annual General Meeting, May 14, 2025.
お知らせ • Jan 16+ 1 more updateNIOX Group Plc Appoints Jonathan Emms as Chief Executive OfficerNIOX Group Plc announced Jonathan Emms, currently Chief Operating Officer, has been appointed Chief Executive Officer with immediate effect.
お知らせ • Dec 04NIOX Group Plc to Report Fiscal Year 2024 Results on Apr 01, 2025NIOX Group Plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 01, 2025
Reported Earnings • Sep 26First half 2024 earnings released: EPS: UK£0.01 (vs UK£0.007 in 1H 2023)First half 2024 results: EPS: UK£0.01 (up from UK£0.007 in 1H 2023). Revenue: UK£21.0m (up 12% from 1H 2023). Net income: UK£4.40m (up 52% from 1H 2023). Profit margin: 21% (up from 15% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 24NIOX Group Plc (AIM:NIOX) announces an Equity Buyback for 26,250,000 shares, representing 6.19% for £21 million.NIOX Group Plc (AIM:NIOX) announces a share repurchase program. Under the program, the company will repurchase up to 26,250,000 shares, representing 6.19% of its share capital for £21 million. The shares will be repurchased at £0.8 per share. The company intends to hold 10,000,000 shares in treasury and the remaining shares will be cancelled. The record date for the offer is October 15, 2024. The offer will be valid till October 15, 2024. The tender offer is subject to approval from shareholders in the Extraordinary General Meeting to be held on October 16, 2024. As of September 23, 2024, the company has 424,045,460 shares in issue.
お知らせ • Aug 19NIOX Group Plc to Report First Half, 2024 Results on Sep 24, 2024NIOX Group Plc announced that they will report first half, 2024 results on Sep 24, 2024
お知らせ • Jul 01Niox Group plc Appoints Robert Naylor as Non-Executive Director and Chair of the Audit and Risk CommitteeNIOX Group plc announced the appointment of Robert Naylor, aged 49, as Non-Executive Director and Chair of the Audit and Risk Committee, with immediate effect. Robert has over 25 years' experience in capital markets specialising in healthcare and investment companies and is currently Chief Executive Officer of Intuitive Investments Group plc, an investment company which is quoted on the Specialist Fund Segment of the London Stock Exchange's Main Market, providing investors with exposure to a portfolio of fast-growing technology and life sciences businesses. Additionally, Robert is Non-Executive Chairman of Hipgnosis Songs Fund Limited, a FTSE 250 company, which is currently subject to a recommended cash offer by Lyra Bidco Limited, a newly-formed company indirectly wholly-owned by investment funds advised by affiliates of Blackstone Inc. Previously, Robert was Non-Executive Chairman of Round Hill Music Royalty Fund Limited and oversaw its sale to a company directly owned by Alchemy Copyrights, LLC, trading as Concord. He has also served as a Non-Executive Director of Light Science Technologies Holdings plc, an AIM-quoted controlled environment agriculture company. Earlier in his career Robert held various positions within JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited and Cenkos Securities plc. Robert is a qualified chartered accountant, having started his career with Ernst & Young in 1996. Current directorships/partnerships: Intuitive Investments Group Plc, IIG Assets Ltd, Hipgnosis SFH XX Limited, Hipgnosis SFH XIII Limited, Hipgnosis SFH XIX Limited, Hipgnosis SFH I Limited, Hipgnosis Holdings UK Limited, Rubyruby (London) Limited, Pb Songs Ltd, Kennedy Publishing & Productions Limited, Deamon Limited. Past directorships/partnerships: Round Hill Music Royalty Fund Limited, RHMRF2 Limited, RHMRF3 Limited, Light Science Technologies Holdings plc, Concord Copyrights No.1 Limited (formerly RHMRF1 Limited).
Upcoming Dividend • May 16Upcoming dividend of UK£0.01 per shareEligible shareholders must have bought the stock before 23 May 2024. Payment date: 24 June 2024. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.7%).
お知らせ • Apr 05NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024NIOX Group Plc announced on 26 March 2024 a proposed final dividend of 1.0 pence per ordinary share in respect of the financial year ended 31 December 2023. The proposed dividend is subject to shareholder approval at the Company's Annual General Meeting ("AGM") to be held on 22 May 2024. Following approval, the dividend will be paid on 24 June 2024 to shareholders on the register at the close of business on the record date of 24 May 2024, with an ex-dividend date of 23 May 2024.
Recent Insider Transactions • Mar 31COO & Executive Director recently sold €171k worth of stockOn the 28th of March, Jonathan Emms sold around 234k shares on-market at roughly €0.73 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months.
Reported Earnings • Mar 26Full year 2023 earnings releasedFull year 2023 results: Revenue: UK£36.8m (up 18% from FY 2022). Net income: UK£9.50m (down 33% from FY 2022). Profit margin: 26% (down from 45% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.
お知らせ • Dec 27+ 1 more updateNIOX Group Plc, Annual General Meeting, May 22, 2024NIOX Group Plc, Annual General Meeting, May 22, 2024.
Reported Earnings • Sep 28First half 2023 earnings released: EPS: UK£0.007 (vs UK£0.021 in 1H 2022)First half 2023 results: EPS: UK£0.007 (down from UK£0.021 in 1H 2022). Revenue: UK£18.8m (up 21% from 1H 2022). Net income: UK£2.90m (down 67% from 1H 2022). Profit margin: 15% (down from 57% in 1H 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth.
New Risk • Sep 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 23% Last year net profit margin: 46% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (23% net profit margin).
お知らせ • Jul 21NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023NIOX Group Plc announced a special dividend of 2.5 pence per share (equating to a return of cash of approximately £10.5 million) will be paid on 15 September 2023 to shareholders on the register as at the close of business on Friday 18 August 2023. The Group is now generating sufficient operating cashflow to permit both continued investment in the development of its business and the payment of ongoing dividends to shareholders.
お知らせ • Jun 07NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023NIOX Group Plc announced that a special dividend of 2.5 pence per ordinary share will be paid on 15 September 2023 to shareholders on the register as at 18 August 2023. The associated ex-dividend date will be 17 August 2023.
Board Change • Apr 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Mar 30COO & Executive Director recently sold €114k worth of stockOn the 28th of March, Jonathan Emms sold around 227k shares on-market at roughly €0.50 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months.
Reported Earnings • Mar 22Full year 2022 earnings released: EPS: UK£0.034 (vs UK£0.006 in FY 2021)Full year 2022 results: EPS: UK£0.034 (up from UK£0.006 in FY 2021). Revenue: UK£31.3m (up 12% from FY 2021). Net income: UK£14.1m (up UK£11.8m from FY 2021). Profit margin: 45% (up from 8.2% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 17NIOX Group Plc to Report Fiscal Year 2022 Results on Mar 21, 2023NIOX Group Plc announced that they will report fiscal year 2022 results on Mar 21, 2023
Board Change • Oct 31High number of new directorsNon-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020.
Reported Earnings • Sep 16First half 2022 earnings released: EPS: UK£0 (vs UK£0.005 loss in 1H 2021)First half 2022 results: EPS: UK£0 (improved from UK£0.005 loss in 1H 2021). Revenue: UK£15.5m (up 6.2% from 1H 2021). Net income: UK£8.90m (up UK£10.9m from 1H 2021). Profit margin: 57% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.
お知らせ • Jul 14Circassia Group Plc to Report First Half, 2022 Results on Sep 14, 2022Circassia Group Plc announced that they will report first half, 2022 results on Sep 14, 2022
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 14Circassia Group Plc, Annual General Meeting, May 13, 2022Circassia Group Plc, Annual General Meeting, May 13, 2022, at 09:00 Coordinated Universal Time. Location: Northbrook House, Robert Robinson Avenue, Oxford Science park Oxford United Kingdom
Recent Insider Transactions • Apr 02Executive Chairman recently bought €64k worth of stockOn the 29th of March, Ian Johnson bought around 150k shares on-market at roughly €0.43 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €197k worth in shares.
Reported Earnings • Sep 18First half 2021 earnings released: UK£0.005 loss per share (vs UK£0.027 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£14.6m (up 28% from 1H 2020). Net loss: UK£2.00m (loss narrowed 79% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 18Executive Chairman recently bought €65k worth of stockOn the 16th of September, Ian Johnson bought around 150k shares on-market at roughly €0.43 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €133k worth in shares.
お知らせ • May 27Beyond Air, Inc. Enters into Settlement Agreement with Circassia Group plcOn May 26, 2021, Beyond Air, Inc. entered into a settlement agreement with Circassia Group plc. Under the terms of the Settlement Agreement, the Company retains United States and China commercialization rights to LungFit® PH in exchange for returning $10.5 million in upfront and milestone payments received by the Company in 2019, over a two-year period commencing after the LungFit® PH receives United States Food and Drug Administration approval. Beginning in year three post-approval, Circassia will receive a quarterly royalty payment equal to 5% of LungFit® net sales in the United States, which will terminate once the aggregate payment reaches $6.0 million. The Company now holds full global rights to LungFit® PH.
Recent Insider Transactions • Apr 08Executive Chairman recently bought €67k worth of stockOn the 6th of April, Ian Johnson bought around 200k shares on-market at roughly €0.34 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €120k worth in shares.
Reported Earnings • Mar 25Full year 2020 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: UK£23.9m (down 62% from FY 2019). Net loss: UK£26.8m (loss narrowed 45% from FY 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
お知らせ • Jan 28Circassia Group Plc(AIM:CIR) dropped from FTSE All-Share Index (GBP)Circassia Group Plc(AIM:CIR) dropped from FTSE All-Share Index (GBP)
お知らせ • Nov 13Circassia Group Plc Appoints Nicholas Mills as Non-Executive DirectorCircassia Group Plc announced the appointment of Nicholas Mills as Non-Executive Director, effective 13 November 2020. Nicholas is employed by Harwood Capital LLP. Nicholas joined Harwood Capital LLP in 2019 after spending five years at Gabelli Asset Management in New York. He acted primarily as a Research Analyst covering the multi-industrial space and also gained experience in Merger Arbitrage strategies and marketing Closed End Funds.
お知らせ • Sep 02An unknown buyer acquired 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited for £3.9 million.An unknown buyer acquired 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited for £3.9 million on September 1, 2020. An unknown buyer completed the acquisition of 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited on September 1, 2020.